<code id='E4AC06C6F9'></code><style id='E4AC06C6F9'></style>
    • <acronym id='E4AC06C6F9'></acronym>
      <center id='E4AC06C6F9'><center id='E4AC06C6F9'><tfoot id='E4AC06C6F9'></tfoot></center><abbr id='E4AC06C6F9'><dir id='E4AC06C6F9'><tfoot id='E4AC06C6F9'></tfoot><noframes id='E4AC06C6F9'>

    • <optgroup id='E4AC06C6F9'><strike id='E4AC06C6F9'><sup id='E4AC06C6F9'></sup></strike><code id='E4AC06C6F9'></code></optgroup>
        1. <b id='E4AC06C6F9'><label id='E4AC06C6F9'><select id='E4AC06C6F9'><dt id='E4AC06C6F9'><span id='E4AC06C6F9'></span></dt></select></label></b><u id='E4AC06C6F9'></u>
          <i id='E4AC06C6F9'><strike id='E4AC06C6F9'><tt id='E4AC06C6F9'><pre id='E4AC06C6F9'></pre></tt></strike></i>

          knowledge

          knowledge

          author:entertainment    Page View:9
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more
          Why Eli Lilly’s earnings didn’t quite live up to the hype
          Why Eli Lilly’s earnings didn’t quite live up to the hype

          KristofferTripplaar/APEventually,theluckiestcompaniesgettodealwithaveryparticularproblem:whattodowhe

          read more
          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more

          Trans patients at the end of life deserve respect and dignity

          JohnMoore/GettyImagesIntheUnitedStates,morethan1.6millionpeopleidentifyastransgender.Ofthese,moretha